Interactions of vascular endothelial growth factor and p53 with miR-195 in thyroid carcinoma: possible therapeutic targets in aggressive thyroid cancers

H Maroof, S Irani, A Arianna, J Vider… - Current cancer drug …, 2019 - ingentaconnect.com
Background: The clinical pathological features, as well as the cellular mechanisms of miR-
195, have not been investigated in thyroid carcinoma. Objective: The aim of this study is to …
被引用次数：23 相关文章
[PDF] researchgate.net

[PDF][PDF] Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thy-roid Cancers

H Maroofa, S Irania, A Ariannaa, J Viderc… - Current Cancer Drug …, 2018 - researchgate.net
Background: The clinical pathological features, as well as the cellular mechanisms of miR-
195, have not been investigated in thyroid carcinoma. Objective: The aim of this study is to …

Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers.

H Maroof, S Irani, A Arianna, J Vider… - Current Cancer Drug …, 2019 - europepmc.org
Background The clinical pathological features, as well as the cellular mechanisms of miR-
195, have not been investigated in thyroid carcinoma. Objective The aim of this study is to …

Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers

H Maroof, S Irani, A Arianna, J Vider… - … cancer drug targets, 2019 - pubmed.ncbi.nlm.nih.gov
Background The clinical pathological features, as well as the cellular mechanisms of miR-
195, have not been investigated in thyroid carcinoma. Objective The aim of this study is to …